Phathom Pharmaceuticals (PHAT) Earnings Analysis
Phathom Pharmaceuticals (PHAT) next reports earnings on 2026-07-30, consensus EPS -0.06 USD. Last quarter (2026-04-30) it missed with EPS -0.37 USD vs -0.27 USD est (-37%). It has beaten estimates in 4/7 recent quarters (57%). Trailing P/E -5.52.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does PHAT next report earnings?
| Next earnings date | 2026-07-30 |
|---|---|
| Consensus EPS estimate | -0.06 USD |
| Revenue estimate | 0.07B |
PHAT earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-30 | -0.37 USD | -0.27 USD | -37% | Miss |
| 2026-02-26 | -0.16 USD | -0.31933 USD | +49.9% | Beat |
| 2025-10-30 | -0.15 USD | -0.3 USD | +50% | Beat |
| 2025-05-01 | -1.07 USD | -1.06 USD | -0.9% | Miss |
| 2025-03-06 | -0.79 USD | -1.29 USD | +38.8% | Beat |
| 2024-11-07 | -1.32 USD | -1.57 USD | +15.9% | Beat |
| 2024-08-08 | -1.25 USD | -1.2 USD | -4.2% | Miss |
Beat rate: 4/7 (57%) over reported quarters with consensus data.
PHAT valuation and analyst view
| Trailing P/E | -5.52 |
|---|---|
| Trailing EPS | -1.91711 USD |
| Price / book | -2.85 |
| Dividend yield | 0.00% |
| Market cap | 0.91B |
| Analyst consensus | Buy (8 buy / 1 hold / 0 sell) |
| Avg price target | 22.57 USD |
Related research pages
Frequently asked questions
When is Phathom Pharmaceuticals (PHAT)'s next earnings date?
Phathom Pharmaceuticals is next scheduled to report on 2026-07-30, with a consensus EPS estimate of -0.06 USD and revenue estimate of 0.07B.
Did PHAT beat earnings last quarter?
In its 2026-04-30 report, PHAT posted EPS of -0.37 USD versus a -0.27 USD estimate — a miss of 37%.
What is PHAT's earnings track record?
Over the last 7 reported quarters with consensus data, PHAT beat estimates 4 times (57%).
What is PHAT's current P/E ratio and EPS?
PHAT trades at a trailing P/E of -5.52 on trailing EPS of -1.9171092654049235 USD.
What do analysts rate PHAT?
Analyst consensus is "Buy" across 9 ratings (0 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 22.57 USD.